Table 1 Study characteristics
Authors | No. of center | No. of patients | Male | Age | Tumor from AV | ||||
|---|---|---|---|---|---|---|---|---|---|
JP | SE | JP | SE | JP | SE | JP | SE | ||
Doeksen | 7 | 55 | 52 | 36 | 37 | 61.8/12.3 | 63.8/8.8 | NR | NR |
Huber | 1 | 29 | 30 | 13 | 12 | 62.3 | 61.9 | 5.2/1.6 | 5.8/1.5 |
Jiang | 1 | 24 | 24 | 12 | 15 | 62.3/3.3 | 64.9/2.8 | 7.9/1.5 | 8.6/0.3 |
Machado | 1 | 50 | 50 | 27 | 32 | 63.8/11.3 | 65.0/11.8 | 9.5/3.0 | 9.8/2.8 |
Marti | 15 | 63 | 95 | 38 | 62 | 63.4/13.7 | 63.9/9.5 | 6.0/2.5 | 7.5/2.3 |
Okkabaz | 1 | 29 | 28 | 18 | 19 | 58.9/13.7 | 59.1/11.9 | 7.9/3.8 | 6.2/3.8 |
Parc | 7 | 80 | 87 | 59 | 52 | 60.2/9.7 | 59.6/10.6 | 2.5/0.7 | 2.0/0.7 |
Authors | Anastomosis from AV | Neoadjuvant therapy | Adjuvant therapy | Quality of life assessment scale | |||
|---|---|---|---|---|---|---|---|
JP | SE | JP | SE | JP | SE | ||
Doeksen | NR | NR | 55 | 52 | 0 | 0 | COREFO, EORTC-QLQ-CR38, SF-36 |
Huber | 3.8/0.8 | 4.2/0.5 | NR | NR | NR | NR | NA |
Jiang | 4.8/0.2 | 5.3/0.3 | 12 | 10 | 2 | 1 | NA |
Machado | 4.0/1.0 | 3.8/0.8 | 39 | 39 | 4 | 2 | NA |
Marti | NR | NR | 49 | 72 | 34 | 53 | FACT-C |
Okkabaz | NR | NR | 17 | 19 | NR | NR | SF-36, SHIM, FISI, FSFI, OBVF |
Parc | NR | NR | 42 | 50 | NR | NR | SF-12, FACT-C, IIEF, FISI |